Novavax (NVAX) Share-based Compensation (2010 - 2026)
Novavax (NVAX) posted quarterly Share-based Compensation of $7.7 million for Q1 2026, down 24.9% year-over-year from $10.3 million in Q1 2025, and down 3.05% quarter-over-quarter from $8.0 million in Q4 2025.
Novavax (NVAX) Share-based Compensation (2010 - 2026) Analysis & Trends
Novavax's Share-based Compensation history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 24.9% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $33.5 million (down 28.64% YoY), while the FY2025 annual figure was $36.0 million, down 25.21% from the prior year.
- Share-based Compensation for Q1 2026 stood at $7.7 million, down from $8.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $102.5 million in Q3 2022, with the low at -$32.9 million in Q2 2022.
- The 5-year median for Share-based Compensation is $11.6 million (2024), against an average of $18.1 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation tumbled 161.99% in 2022, then soared 162.26% in 2024.
- Novavax's Share-based Compensation stood at $27.8 million in 2022, then sank by 43.63% to $15.7 million in 2023, then slumped by 33.27% to $10.4 million in 2024, then retreated by 23.75% to $8.0 million in 2025, then slipped by 3.05% to $7.7 million in 2026.
- Business Quant data shows NVAX's Share-based Compensation at $7.7 million in Q1 2026, $8.0 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 8.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.09 Mn |
| Jun 30, 2026 | 8.09 Mn |
| Mar 31, 2026 | 7.72 Mn |
| Mar 31, 2026 | 7.72 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Sep 30, 2025 | 8.55 Mn |
| Sep 30, 2025 | 8.55 Mn |
| Jun 30, 2025 | 9.21 Mn |
| Jun 30, 2025 | 9.21 Mn |
| Mar 31, 2025 | 10.29 Mn |
| Mar 31, 2025 | 10.29 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Dec 31, 2024 | 10.45 Mn |
| Sep 30, 2024 | 12.05 Mn |
| Sep 30, 2024 | 12.05 Mn |
| Jun 30, 2024 | 14.10 Mn |
| Jun 30, 2024 | 14.10 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Mar 31, 2024 | 11.56 Mn |